DR. LILIAN ANTWI BOATENG WINS US$150,000 GLOBAL RESEARCH AWARD TO DEVELOP AFRICAN-SPECIFIC BLOOD GROUP TESTING REAGENTS

Dr. Lilian Antwi Boateng, a Senior Lecturer in the Department of Medical Diagnostics at the Kwame Nkrumah University of Science and Technology (KNUST) and Lead Scientist of the University’s Immunohaematology Research Group, has received a US$150,000 Global Research Award from the American Society of Hematology (ASH) to advance immunohaematology research in Africa.

The research award will support a project titled “Study of African Blood Group Antigens for the Development of Reagents to Detect Associated Antibodies.”

The research addresses a specific challenge in transfusion medicine: the availability of blood-group testing reagents that adequately represent the genetic and antigenic diversity of African populations.

Blood transfusion depends on compatibility between donors and recipients. In addition to the major ABO and Rh blood-group systems, human red blood cells carry numerous other antigens. When a patient develops antibodies against an antigen that is present on transfused red blood cells but absent from the patient’s own cells, complications can arise during subsequent transfusions.

Dr. Antwi Boateng’s project seeks to investigate African blood-group antigens and their associated antibodies with the longer-term objective of contributing to an African-specific reagent red-cell panel for antibody testing.

The project is particularly relevant to transfusion laboratories because reagent cells used for antibody screening and identification are often sourced internationally. The research seeks to generate evidence on whether reagent panels can be better adapted to the blood-group characteristics of African populations.

The project will be conducted through the Immunohaematology Research Group at KNUST and is positioned within a broader effort to strengthen transfusion-science research capacity in Africa.

The award provides resources for scientific investigation, laboratory work and research development. It also gives the research team an opportunity to generate evidence that can contribute to future development of diagnostic reagents designed around African population characteristics.

The project does not mean that a new commercial diagnostic reagent has already been developed. Rather, the research seeks to establish the scientific evidence necessary for the development of an African-specific testing approach.

The research could ultimately contribute to improved understanding of alloantibodies, blood-group antigen distribution and transfusion compatibility among African populations, subject to the findings generated through the project.

The award therefore recognises both the researcher and a research programme addressing a specific scientific and clinical gap in transfusion medicine.